Management of HBV Reactivation in Patients Receiving Rituximab

Patient Assessment

• Patients with resolved HBV infection (HBsAg‑negative, anti‑HBc positive, anti‑HBs positive) who develop HBV DNA > 1,000 IU/mL while on rituximab are considered to have HBV reactivation and require therapeutic antiviral management even if transaminases are normal. 1

Antiviral Therapy

• Entecavir should be continued and not discontinued; documented reactivation (HBV DNA > 1,000 IU/mL) mandates ongoing treatment rather than prophylaxis. 1, 2
• Entecavir is the preferred first‑line agent for treating HBV reactivation in this setting because of its high barrier to resistance. 2, 3, 4
• The therapeutic goal is to suppress HBV DNA to undetectable levels and maintain suppression throughout the high‑risk period. 2, 3

Duration of Antiviral Therapy

• Continue entecavir for at least 12 months after the last rituximab dose because rituximab‑induced B‑cell depletion can delay immune reconstitution and prolong reactivation risk. 2, 5, 4, 6
• The risk of HBV reactivation may persist 1–2 years after the final rituximab infusion; therefore, extended antiviral coverage is advisable. 5, 4, 6
• After completing rituximab, patients should be monitored for late reactivation for up to 2 years. 4, 6

Monitoring During Rituximab Therapy

• Perform HBV DNA and ALT testing every 3 months while the patient is receiving rituximab. 2, 3, 4
• Normal ALT values do not exclude significant reactivation; asymptomatic rises in HBV DNA are common and differ from overt hepatitis flares. 1

Monitoring After Rituximab Discontinuation

• After stopping entecavir, check ALT monthly for the first 3 months, then every 3 months thereafter to detect possible withdrawal flares. 2
• Continue HBV DNA surveillance every 3–6 months for at least 12–24 months after the last rituximab dose to identify delayed reactivation. 5, 4, 6

Clinical Pitfalls

• Do not discontinue entecavir solely because transaminases are normal; early, asymptomatic HBV DNA elevation represents reactivation that requires treatment to prevent progression to hepatitis flare, hepatic decompensation, or death. 1, 2

Specialist Coordination

• Arrange care with a clinician experienced in HBV management to determine the appropriate long‑term antiviral therapy duration after rituximab completion, based on ongoing HBV DNA trends and HBsAg status. 2